Ironwood Pharmaceuticals (IRWD) Downgraded to “Sell” at BidaskClub

BidaskClub cut shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from a hold rating to a sell rating in a research note published on Saturday morning.

Several other equities analysts have also recently issued reports on the company. Credit Suisse Group started coverage on Ironwood Pharmaceuticals in a research note on Monday, November 27th. They issued a buy rating and a $19.00 price objective for the company. ValuEngine cut Ironwood Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, November 14th. Mizuho cut Ironwood Pharmaceuticals from a buy rating to a neutral rating and decreased their price objective for the company from $20.00 to $16.00 in a research note on Wednesday, December 6th. Finally, Morgan Stanley restated a hold rating on shares of Ironwood Pharmaceuticals in a research note on Monday, December 4th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $17.88.

Ironwood Pharmaceuticals (IRWD) opened at $14.99 on Friday. The company has a debt-to-equity ratio of -22.31, a current ratio of 4.87 and a quick ratio of 4.86. The stock has a market capitalization of $2,244.83, a PE ratio of -15.45 and a beta of 1.44. Ironwood Pharmaceuticals has a 52 week low of $13.43 and a 52 week high of $19.94.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.07. The business had revenue of $86.80 million during the quarter, compared to analysts’ expectations of $73.59 million. Ironwood Pharmaceuticals had a negative return on equity of 645.22% and a negative net margin of 48.89%. The business’s quarterly revenue was up 31.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.18) EPS. sell-side analysts expect that Ironwood Pharmaceuticals will post -1.12 earnings per share for the current fiscal year.

In related news, CEO Peter M. Hecht sold 113,405 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $15.12, for a total transaction of $1,714,683.60. Following the completion of the sale, the chief executive officer now owns 4,696,917 shares in the company, valued at $71,017,385.04. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 115,769 shares of company stock valued at $1,752,491. 7.63% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. lifted its stake in Ironwood Pharmaceuticals by 5.8% during the second quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 648 shares during the last quarter. Aperio Group LLC lifted its stake in Ironwood Pharmaceuticals by 11.9% during the second quarter. Aperio Group LLC now owns 13,213 shares of the biotechnology company’s stock worth $249,000 after purchasing an additional 1,410 shares during the last quarter. Amalgamated Bank lifted its stake in Ironwood Pharmaceuticals by 9.0% during the second quarter. Amalgamated Bank now owns 17,280 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 1,421 shares during the last quarter. Virtu KCG Holdings LLC lifted its stake in Ironwood Pharmaceuticals by 10.3% during the second quarter. Virtu KCG Holdings LLC now owns 15,740 shares of the biotechnology company’s stock worth $297,000 after purchasing an additional 1,470 shares during the last quarter. Finally, Legal & General Group Plc lifted its stake in Ironwood Pharmaceuticals by 5.0% in the second quarter. Legal & General Group Plc now owns 47,773 shares of the biotechnology company’s stock valued at $900,000 after buying an additional 2,265 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/12/31/ironwood-pharmaceuticals-irwd-downgraded-to-sell-at-bidaskclub.html.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit